Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × OTHER × epratuzumab × Clear all

Phase

Phase 2 3 Phase NA 1 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Burkitt Lymphoma 1

Interventions

Cyclophosphamide 220 Radiotherapy 157 Carboplatin 136 pembrolizumab 134 Nivolumab 127 Gemcitabine 126 Paclitaxel 121 Cisplatin 105 fludarabine 102 Dexamethasone 102 Lenalidomide 93 Rituximab 90 Docetaxel 90 Bevacizumab 86 Capecitabine 85 Temozolomide 84 fludarabine phosphate 81 Cytarabine 79 Oxaliplatin 76 Irinotecan 70 Etoposide 70 Filgrastim 69 Melphalan 65 Doxorubicin 65 venetoclax 64 Peripheral Blood Stem Cell Transplantation 63 Fluorouracil 61 Everolimus 60 Radiosurgery 57 durvalumab 55

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01279707 2014-07-14

MARALL

Queen Mary University of London

Phase 1/2 Unknown

Burkitt Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡